In summary, as any cancer cell overexpresses the NK-1R and SP promotes the mitogenesis of these cells, a common therapeutic strategy against any tumor type (solid and non-solid) is possible: the use of NK-1R antagonists (Figure 1). The gene discussed is TACR1; the disease is neoplasm.